Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at BioCentury’s 24^th Annual NewsMakers in the Biotechnology Industry Conference.

Event:           BioCentury NewsMakers Conference

Date:            September 8, 2017

Time:            10:30 – 10:55 a.m. ET

Location:      New York, NY

A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.

About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Contacts for Adverum:

Charles Butler
Vice President, Investor Relations &
Corporate Communications
650-272-6260
cbutler@adverum.com

Adverum Biotechnologies, Inc.